The Global Pharmaceutical Leaders’ Club proudly welcomes Olainfarm as a “Pharmaceutical Partner” for the second consecutive year at the Eurasian Pharmaceutical Summit, set to take place in Tashkent and online on the 17th – 19th September.
Elena Bushberg, Executive Director of Olainfarm, will take the stage as a speaker at the Eurasian Pharmaceutical Summit. She emphasized the strategic importance of Central Asian countries, highlighting initiatives to expand staff, invest in technology, and drive educational activities. Bushberg underscores the summit’s role in gaining insights into regional developments, new regulations, and emerging trends to navigate them effectively.
With over 50 years of market expertise, Olainfarm specializes in producing pharmaceutical drugs for nervous and cardiovascular system disorders, along with antiviral, antibacterial, and antiallergic medicines. Its products are distributed across 60+ countries.
Join industry leaders at the Eurasian Pharmaceutical Summit to explore market trends in Central Asia, the Caucasus, and Eastern Europe!
We can’t wait to see you in-person and online this autumn!
Olainfarm consistently participates in the Eurasian Pharmaceutical Summit, a premier event organised by the Global Pharmaceutical Leaders’ Club. For the second consecutive year, the company proudly supports this pivotal gathering as a “Pharmaceutical Partner”. Elena Bushberg, Executive Director of Olainfarm spoke with Natalia Baeva, Director of the Global Pharmaceutical Leaders’ Club, about the company’s strategy in the region, its approach to partner relationships and the execution of digital projects.
Natalia Baeva, Director of the Global Pharmaceutical Leaders’ Club: Olainfarm has been an active participant in the Eurasian Pharmaceutical Summit for several years, underscoring the region’s significance to your company. Could you elaborate on the strategy you’re pursuing in this region?
Elena Bushberg, Executive Director of Olainfarm: Central Asia holds a pivotal role in our strategic focus. After a thorough analysis of economic indicators and growth prospects, we’ve aligned our strategy accordingly. The region’s politics also factor significantly into our decision-making. We identified key countries for expanding our workforce, investing in technology, and fostering educational initiatives. Notably, in Uzbekistan, we recognize the government’s initiative as catalysts for rapid economic advancement.
The summit provides a unique chance to delve into the dynamics of these countries, staying abreast of new regulations and emerging trends to navigate them adeptly. Take serialization, for instance, already in force in Uzbekistan and soon to roll out in Kazakhstan and Kyrgyzstan. Our conference engagements have been instrumental in grasping these requirements and adjusting accordingly. Case in point: in Uzbekistan, we pioneered supplying labeled products from overseas. We’re geared up to tackle similar challenges in Kazakhstan and Kyrgyzstan with equal success.
Natalia Baeva, Director of the Global Pharmaceutical Leaders’ Club: Tell us what approach you take when developing relationships with partners.
Elena Bushberg, Executive Director of Olainfarm: We firmly believe that strong partnerships are the cornerstone of business growth. When selecting partners, we meticulously assess their operations in their respective countries, as this is crucial to us. We prioritize sincerity and transparency in our relationships, fostering trust as the foundation for collaboration. At the Eurasian Pharmaceutical Summit 2023, we were honored to receive the “Partnership of the Year” award for our collaboration with Meros Pharm. Prior to forging an exclusive partnership with them, we thoroughly evaluated their market operations, growth strategies, approached to staff development and motivation, and logistics schemes. This firsthand experience cemented our decision to embark on an exclusive partnership, propelling us forward together and injecting fresh momentum into our endeavors.
Natalia Baeva, Director of the Global Pharmaceutical Leaders’ Club: Over the past two years, you’ve also been honored with awards in the “Digital Project of the Year” category. What guiding principles does the company follow when developing and executing digital initiatives?
Elena Bushberg, Executive Director of Olainfarm: The crux of our digital projects lies in a broader philosophy beyond mere channel digitalization, as channels merely serve as conduits for conveying key messages. Patient-centricity is paramount in all our digital endeavors. Recognizing the challenges patients face in acknowledging their needs and accepting their situations, we prioritize emotional well-being and access to information. Rather than selecting digital tools first, we craft concepts on effective patient communication and doctor-patient rapport. Take “Cosmic Calm”, for instance. In response to rising anxiety levels globally, especially among young patients, this project aims to foster trust between parents and doctors. By providing valuable insights into symptoms and enabling seamless communication, it empowers parents to intervene early while granting doctors access to patient diaries for tailored treatment. Launched in Kazakhstan and Uzbekistan, this initiative involves approximately 3,000 neurologists collaborating with parents and young patients.
Olainfarm and Zdorovie.ru have become the winners in the nomination “Digital Project of the Year” of the contest for the Eurasian Pharma Awards 2023 for the joint project “In the Rhythm of the Heart”.
The project enables cardiologists and patients with atrial fibrillation to remotely monitor the patient’s condition and ECG parameters for those undergoing antiarrhythmic therapy. This allows assessing the effectiveness and safety of pharmaceutical drugs therapy and enabling informed clinical decisions. The project was implemented by Olainfarm using Zdorovie.ru and Zdorovie.ru Doctor applications.
Andrey Moskvich, the General Director at Olainfarm Russia and Eric Brovko, the Founder and CEO at the Zdorovie.ru platform, were invited to receive awards.
Upon receiving the award, Andrey Moskvich highlighted: “This recognition means that we are heading in the right direction. It will motivate us to develop the project further and help more patients. This is the result of cooperative work of Olainfarm together with the cardiology community and our long-term partner, the Zdorovie.ru team”.
Eric Brovko emphasized: “For us, it is truly valuable to receive such an award because recognition motivates us to drive innovations. This partnership could not be successful without two important principles. First and foremost, it is trust that forms the basis of our relationships, and secondly, it is tolerance for mistakes and a culture of innovation that unites.
Uzbek pharmacy chain “OXYmed” is one of the winners in the nomination “Pharmacy Chain of the Year” of the contest for the Eurasian Pharma Awards 2023.
The history of the pharmacy chain “OXYmed” dates back to 2003. Today, it includes 115 pharmacies, with over 80 of them located in Tashkent and the rest in various regions of the country. Over the years, a well-established network of suppliers has been developed. The supply chain from a supplier to a pharmacy is minimized, as “OXYmed” either directly collaborates with manufacturing plants or with large national companies. The pharmacy’s assortment includes not only a wide range of medicines but also herbal teas, dietary supplements, and beauty products.
Nargiza Madaliyeva, Interim CEO of the pharmacy chain “OXYmed”, upon receiving the award, thanked all the partners and clients without whom this victory would have been impossible.
In 2023 in the competition for the Eurasian Pharma Awards in the nomination “Partnership of the Year” the award was presented to Olainfarm and Meros Pharm.
The transformation of collaboration between Olainfarm, a leading pharmaceutical company in the Baltics, and Meros Pharm, a leader in pharmaceutical distribution in Uzbekistan, along with increased investments in product promotion and improvements in both international and local logistics, has yielded tangible results that allow to develop ambitious plans for the future. The exclusive agreement has ensured the availability of Olainfarm products in over 4,000 pharmacies and has led to a 65% increase in sales compared to the previous year.
Elena Bushberg, Executive Director of Olainfarm, highlighted: «As a proverb says a tree is held by its roots, and a person is held by their family and heritage. I would add that success in business is held by good partners».
In 2023 in the competition for the Eurasian Pharma Awards in the nomination “Partnership of the Year” the award was given to the company Stada for the project in collaboration with Sanofi.
Stada and Sanofi have entered into a long-term agreement for the distribution of the CHC product portfolio in the Eurasian region. Since April of this year, Stada has been handling the distribution and marketing support for Sanofi’s products in 10 countries in the Eurasian region. The distribution agreement with Stada has strengthened its position as a leading company in the Consumer Healthcare segment in the region.
Arminas Macevicus, Vice President of Stada in the Eurasian region, highlighted: “This is an important recognition for us. I’d like to wish everyone to dream as when we dream big even the toughest negotiations lead to very positive solutions!”
The company “Medservice Plus” from Kazakhstan has become the winner in the nomination “Distributor of the Year” of the competition for the Eurasian Pharma Awards 2023.
“Medservice Plus” has been operating in the market of Kazakhstan for over 25 years and over these years has become a market leader having established itself as a reliable partner committed to providing customers with the highest quality medicines and innovative solutions. The company has developed partnerships with 350 producers worldwide, allowing it to supply over 7000 names of pharmaceutical drugs and medical products to the Kazakhstan market.
Saida Yerdenbekova, Member of the Board – Business Development Director at “Medservice Plus” emphasized the importance of recognizing the company’s work at the level of the Eurasian region and added that such competitions inspire further development and increase personnel motivation.
The Kazakh company SANTO, a member of the Polpharma Group of Companies, is the winner in 2 nominations of the contest for the Eurasian Pharma Awards 2023. The company has become the best in nominations “Local Company of the Year” and “Exporter of the Year”.
SANTO is a leading pharmaceutical company in Central Asia, its medicines portfolio includes more than 240 names in 12 pharmacotherapeutic groups. The company is implementing the major investment project to modernize existing pharmaceutical production facilities in accordance with the international GMP standards, which financing has already amounted to around 108 million dollars.
SANTO supplies effective, safe and high quality pharmaceutical drugs to the market of Kazakhstan; the company’s products are exported to Kyrgyzstan, Uzbekistan, Russia, Mongolia, Turkmenistan and Tajikistan. At the moment, SANTO is exploring opportunities for export of medicines to Afghanistan. In 2022 the share of export from total sales exceeded 25%. The market of Kyrgyzstan especially stands out – since the opening of the representative office there in 2015 the company’s position reached the leading place in this country. So SANTO is currently number one not only in Kazakhstan but also in Kyrgyzstan. Uzbekistan also demonstrates an increase in sales.
Managing Director of SANTO Adam Aleksiejuk and Country Manager of SANTO in Uzbekistan Mirolim Fayziev were invited to the stage to receive awards.
Adam Aleksiejuk thanked the organizers for the opportunity to participate in such a large-scale event and highlighted: “At SANTO, we consider Central Asia as the most promising region for the Polpharma Group of Companies and undoubtedly we see Uzbekistan as the country with the prospects for future growth”.
Mirolim Fayziev emphasized: “Indeed, in Kazakhstan SANTO is the largest local company and a major exporter. Rapidly developing Uzbekistan is very attractive for investors. I hope that in the future the company will be localized in Uzbekistan as well and will become not only an importer but also a large exporter”.
Uzbek company NIKA PHARM has become the winner in the nomination “Local Company of the Year” at the Eurasian Pharma Awards 2023 contest.
NIKA PHARM is consistently among the top three local producers in Uzbekistan. The company has already registered more than 100 pharmaceutical drugs and 37 dietary supplements. The company’s products are promoted both in the Uzbek market and overseas. NIKA PHARM is continuously working to improve product quality, and confirmation by international inspections open the gateway for them to new markets. Agreements with the European Bank for Reconstruction and Development further validate NIKA PHARM’s status as a steadily developing company.
Sergey Kim, CEO of NIKA PHARM, expressed his gratitude to the organisers for the opportunity to participate in such a high-level event and thanked them for the awards and received recognition.
Solgar has become the winner of the competition for the Eurasian Pharma Awards 2023 in the nomination “International Company of the Year”.
Solgar has been producing unique premium dietary supplements for over 75 years. Today, company’s products are presented in more than 65 countries around the world, the product range includes more than 600 names. The company has been operating in the markets of the Eurasia region for 15 years and continues to expand its presence, fulfilling a global mission to develop a culture of nutrient responsible consumption among the population and educate the medical and pharmaceutical community.
CEO of Solgar Russia & CIS Hakan Erturk receiving the award thanked the organisers for the opportunity to speak to a high-level audience at the Eurasian Pharmaceutical Summit, held by the Global Pharmaceutical Leaders’ Club, and discuss issues in the pharmaceutical markets of Eurasia region and prospects for the development of the dietary supplement segment.
